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ABSTRACT 
Background: To determine the recommended dose (RD) of a combination of PM01183 
and gemcitabine in patients with advanced solid tumors. 
Methods: Forty-five patients received escalating doses of PM01183/gemcitabine on 
Days 1 and 8 every 3 weeks (d1,8 q3wk) following a standard 3+3 design. 
Results: PM01183 3.5 mg flat dose (FD)/gemcitabine 1000 mg/m2 was the highest dose 
level tested. Dose-limiting toxicities (DLTs) were mostly hematological and resulted in 
the expansion of a lower dose level (PM01183 3.5 mg FD/gemcitabine 800 mg/m2); 19 
patients at this dose level were evaluable but >30% had DLT and >20% had febrile 
neutropenia. No DLT was observed in 11 patients treated at PM01183 3.0 mg 
FD/gemcitabine 800 mg/m2, which was defined as the RD. This regimen was feasible 
and tolerable with manageable toxicity; mainly grade 3/4 myelosuppression. Non-
hematological toxicity comprised fatigue, nausea, vomiting, and transaminases 
increases. Fifteen (33%) patients received ≥6 cycles with no cumulative hematological 
toxicity. Pharmacokinetic analysis showed no evidence of drug-drug interaction. Nine 
of 38 patients had response as per RECIST (complete [3%] and partial [21%]), for an 
overall response rate (ORR) of 24% (95% Confidence Interval [CI] 12–40%). Eleven 
patients (29%) had disease stabilization ≥4 months. Responses were durable (median of 
8.5 months): overall median progression-free survival (PFS) was 4.2 months (95% CI, 
2.7–6.5 months). 
Conclusions: The RD for this combination is PM01183 3.0 mg FD (or 1.6 
mg/m²)/gemcitabine 800 mg/m² d1,8 q3wk. This schedule is well tolerated and has 
antitumor activity in several advanced solid tumor types. 
Key words: PM01183, lurbinectedin, gemcitabine, combination, solid tumor. 
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INTRODUCTION  
PM01183 (lurbinectedin) is a synthetic tetrahydroisoquinoline with broad in vitro and in 
vivo anticancer cytotoxic activity. Its hemiaminal moiety forms a covalent bond with the 
exocyclic amino group of specific guanines in the minor groove of DNA [1,2]. Highly-
specific hydrogen bonds with the nucleotides at both sides of the guanine determine its 
sequence specificity. PM01183-DNA adducts degrade the largest subunit of RNA 
polymerase II (Rpb1) via the ubiquitin-proteasome pathway and inhibit the nucleotide-
excision repair (NER) system [3,4]. PM01183 also inhibits transcription by binding to 
CG-rich sequences, mainly located around promoters of protein-coding genes [5] and 
causes DNA damage that delays progression through the S/G2 phase of the cell cycle 
and induces caspase-dependent apoptotic death [6-8]. PM01183 combined with 
gemcitabine has shown synergism in preclinical models, particularly in pancreatic 
ductal adenocarcinoma (PDA) xenografts [9]. This synergism is the result of enhanced 
DNA damage induced by both drugs, and of the selective depletion of tumor-associated 
macrophages (TAMs) by PM01183 in the tumor stroma. This depletion in turn down 
regulates cytidine deaminase (CDA, an enzyme that catabolizes gemcitabine into its 
inactive metabolite difluorodeoxyuridine [dFdU]) and thus increases the effect of 
gemcitabine. This effect may be particularly relevant in high-density TAM tumors, 
which have been associated with poor prognosis and higher risk of metastasis [10,11]. 
The first-in-human (FiH) study defined a recommended dose (RD) of 4.0 mg/m2 
(equivalent to 7.0 mg flat dose [FD]) for PM01183 given as a 1-h intravenous (i.v.) 
infusion every 3 weeks (q3wk) to advanced cancer patients [12]. Predictable and 
reversible severe myelosuppression, particularly neutropenia, was the limiting toxicity. 
A Day 1 and 8 (d1,8) q3wk schedule was subsequently tested in advanced cancer 
patients, with similar results at a RD of 5.0 mg FD (or 2.8 mg/m2) [13]. 
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Pharmacokinetic (PK) data from the FiH study showed that PM01183 has a relatively 
short half-life (62.7 h) and high inter-patient variability (coefficient of variation [CV] of 
72.6%) at the RD [12]. 
This phase I trial was conducted to determine the RD of PM01183 in 
combination with gemcitabine in patients with advanced solid tumors. The starting 
PM01183 dose, 2.5 mg FD, is equivalent to 50% of the RD for single-agent PM01183 
administered d1,8 q3wk. This schedule is also commonly used with gemcitabine and 
provides an adequate frame for avoiding any significant drug accumulation. The starting 
gemcitabine dose was 800 mg/m2 and could be escalated to 1000 mg/m2 (its full dose in 
most combinations) if a PM01183 FD of 3.5 mg was found to be feasible. 
 
MATERIALS AND METHODS  
The study (NCT number NCT01970553, EudraCT number 2010-024239-18) was 
conducted in Spain and the UK at 3 investigational sites following International 
Conference on Harmonization (ICH) Good Clinical Practice guidelines, and was 
approved by the respective Research Ethics Committees. Informed consent was 
obtained from all individual participants included in the study. 
 
Eligibility Criteria 
Selection criteria included: age 18–75 years; histologically/cytologically confirmed 
diagnosis of advanced malignant disease; ≤2 prior lines of cytotoxic-containing 
chemotherapy for advanced disease; life expectancy ≥3 months; recovery from previous 
toxicities to grade ≤1 (grade ≤2 for alopecia, cutaneous toxicity peripheral sensory 
neuropathy, fatigue); Eastern Cooperative Oncology Group performance status (ECOG 
PS) ≤1; normal left ventricular ejection fraction (LVEF); and adequate bone marrow, 
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hepatic, renal, and metabolic function.  
Criteria for exclusion were: prior treatment with PM01183 or with gemcitabine-
containing therapy for advanced disease (adjuvant therapy was allowed if ≤6 cycles 
were administered and relapse occurred at >6 months); symptomatic progressive or 
corticosteroid-requiring brain metastases or leptomeningeal involvement; pregnancy or 
lactation; radiotherapy to >35% of bone marrow; concomitant conditions such as 
unstable angina, myocardial infarction, congestive heart failure, or clinically significant 
valvular heart disease, symptomatic or uncontrolled arrhythmia requiring treatment, 
chronic hepatopathy, active uncontrolled infection, known human immunodeficiency 
virus (HIV) infection; and a history of prior bone marrow or stem cell transplantation. 
 
Study Treatment 
PM01183 was supplied by Pharma Mar, S.A. (Colmenar Viejo, Madrid, Spain) as a 1.0 
mg/vial of lyophilized powder concentrate for solution for infusion. It was administered 
in escalating doses as a 1-h i.v. infusion d1,8 q3wk. Gemcitabine vials (Gemzar® 1000 
mg and 200 mg) were administered as a 30-min i.v. infusion prior to each PM01183 
administration. 
Patients received standard antiemetic prophylaxis before each administration 
(steroids with serotonin antagonists). Treatment was administered until: disease 
progression; unacceptable toxicity; treatment delay >15 days due to toxicity (except in 
cases of obvious patient benefit); failure to meet retreatment criteria; or requirement of 
>2 dose reductions. 
 
Dose Escalation and Dose-limiting Toxicities 
Dose escalation followed a standard 3+3 design. Dose-limiting toxicities (DLTs) were 
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any of the following events in Cycle 1: grade 4 neutropenia (absolute neutrophil count 
<0.5 × 109/L) lasting >7 days; febrile neutropenia of any duration or neutropenic sepsis; 
grade 4 thrombocytopenia (platelet count <25 × 109/L) or grade 3 with bleeding 
requiring a platelet transfusion; grade 4 alanine aminotransferase (ALT) or aspartate 
aminotransferase (AST) increase, or grade 3 lasting >14 days; treatment-related grade 
≥2 ALT/AST increase concomitantly with ≥2 × upper limit of normal (ULN) total 
bilirubin increase and normal alkaline phosphatase (ALP); grade ≥3 creatine 
phosphokinase increase; any other grade ≥3 non-hematological adverse event (AE) 
suspected to be related to study drugs; delay >15 days in the administration of Cycle 2 
due to any AE related to study drugs. Toxicities occurring after Cycle 1 or non-
compliance with the intended dose intensity could also qualify as DLT. The RD was 
defined as the highest dose level at which less than one third of evaluable patients had 
DLT. 
 
Study Assessments 
Patients were assessed (physical examination, ECOG PS, laboratory tests) at baseline, 
before infusions and at the start of each new cycle. Any clinically-relevant grade ≥3 
abnormalities were reassessed every 2–3 days until recovery to grade ≤1. Febrile 
neutropenia, grade 4 neutropenia, and grade 4 thrombocytopenia were reassessed daily 
until recovery to grade ≤3 or fever resolution, and then every 2–3 days until recovery to 
grade ≤1. Antitumor activity was evaluated radiologically by contrast-enhanced helical 
computed tomography scan or magnetic resonance imaging every 2 cycles (6 weeks). 
 
Pharmacokinetics 
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Fifteen samples were collected to quantify PM01183 plasma concentrations at baseline 
and during the week after the first PM01183 infusion; two more samples on Day 15 and 
Day 22 were collected for the analysis of PM01183 after the Day-8 infusion. PM01183 
was measured by mean of a validated liquid extraction method followed by ultra-
performance liquid chromatography tandem mass-spectrometry (UPLC-MS/MS) 
detection. The calibration range for PM01183 was 0.1–50 ng/mL. Fifteen samples were 
also collected to quantify gemcitabine and its metabolite, dFdU, at baseline and during 
the two days after the end of the first gemcitabine infusion. Gemcitabine and dFdU 
concentrations were measured by a validated method using high performance liquid 
chromatography mass spectrometry (HPLC-MS/MS). The calibration ranges were 
45.57–12570.20 ng/mL and 99.45–12570.20 ng/mL for gemcitabine and dFdU, 
respectively. 
   
Statistical Analysis 
The numbers of patients included, evaluable for DLT, safety, and efficacy were 
summarized by dose level. Safety was evaluated using descriptive statistics. Laboratory 
abnormalities and AEs were graded according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events (NCI-CTCAE) v 4.03. Antitumor activity was 
evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1. 
Response rates were characterized using descriptive statistics (95% exact binomial 
confidence interval [CI]). Overall response rate (ORR) included complete (CR) and 
partial responses (PR). Patients with clinical benefit were those with CR, PR and stable 
disease (SD) ≥4 months.  
Statistical analyses were performed using SAS v 9.2, (SAS Institute Inc, Cary, 
NC, USA) and non-compartmental analysis (NCA) using Phoenix WinNonlin v 6.3 
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(Certara USA Inc, Princeton, NJ, USA). All tests were two-sided; significance was set 
at 0.05. The CV was defined as the ratio of the standard deviation to the mean. 
 
RESULTS 
Patient Characteristics and Treatment 
Forty-five patients were treated between May 2011 and May 2013. Patient 
characteristics are shown in Table 1. A total of 203 cycles were administered, with a 
median of 3 cycles per patient (range, 1–17 cycles). Fifteen patients (33%) received 6 
cycles or more. At the RD, 56 cycles were administered to 11 patients: median number 
of cycles per patient was 4 (range, 2–11 cycles). 
 
Dose-limiting Toxicities and Recommended Dose 
DLT was observed at 2 of the 4 dose levels tested (Table 2). At the highest dose level 
(PM01183 3.5 mg FD/gemcitabine 1000 mg/m²), DLT occurred in 4 of 6 evaluable 
patients (67%): grade 4 thrombocytopenia (n=2); grade 4 neutropenic infection; grade 4 
febrile neutropenia; grade 5 neutropenic sepsis; and omission of Day 8 infusions in 
several cycles due to treatment-related myelosuppression (n=1 each).   
At the immediately lower dose level (PM01183 3.5 mg FD/gemcitabine 800 
mg/m²), DLT were found in 6 of 19 evaluable patients (32%): grade 3/4 febrile 
neutropenia (n=5); grade 4 thrombocytopenia (n=4); and grade 4 hemoptysis that 
resulted in death (n=1). This dose level was considered unfeasible due to the number 
and severity of DLT and to the rate of febrile neutropenia (>20%).  
No DLT occurred in 11 patients treated at the next lower dose level (PM01183 
3.0 mg FD/gemcitabine 800 mg/m²), which therefore was confirmed as the RD. The 
PM01183 dose of 3.0 mg FD corresponds to 1.6 mg/m2 (i.e., 3.0 mg FD divided by 1.9 
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m2, the median body surface area [BSA] at the RD in this study). At the RD this 
schedule was feasible, with acceptable compliance, and delivered the intended dose 
intensity without excessive dose delays. Primary granulocyte-colony stimulating factor 
(G-CSF) prophylaxis was not required according to current guidelines [14], as only one 
of 11 patients (9%) had febrile neutropenia at the RD. 
 
Toxicity Profile 
Myelosuppression was the most frequent abnormality at the RD (Table 3). The most 
common severe hematological abnormalities were neutropenia (55% of patients/36% of 
cycles) and thrombocytopenia (27% of patients/7% of cycles). Grade 4 neutropenia 
(46% of patients/18% of cycles) lasted a median of 3.5 days (range, 2–5 days) and was 
controlled by dose reduction or secondary G-CSF prophylaxis; median time-to-nadir 
was 15 days (range, 7–24 days). 
G-CSF support showed a clear dose relationship: it was given to 40% of patients 
at all dose levels, to 27% at the RD, and to 43% and 56% at the 2 dose levels above the 
RD. Nineteen patients required red blood cell transfusions: 2 (11%) below the RD, 
(37%) at the RD and 10 (53%) above the RD. Nine patients required platelets 
transfusions: one (11%) at the RD and 8 (89%) above the RD. 
The most common biochemical abnormalities at the RD were increases in 
transaminase and creatinine levels (Table 3). Most were mild or moderate, and none 
reached grade 4. Grade 3 abnormalities comprised ALT increase (18% of patients/4% of 
cycles), and AST and ALP increase (9% of patients/2% of cycles each). Of note, grade 
3 transaminases increases with gemcitabine 1000 mg/m2 were almost twice more 
frequent than with 800 mg/m2. 
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 At the RD, the most common treatment-related AEs were fatigue (64% of 
patients/39% of cycles), nausea (55% of patients/21% of cycles) and vomiting (36% of 
patients/11% of cycles) despite antiemetic prophylaxis (Table 3). Most of these AEs 
were mild or moderate, and none reached grade 4. Grade 3 AEs consisted only of single 
episodes of rash (associated with gemcitabine), febrile neutropenia, and fatigue. No 
unexpected toxicity was observed, and the frequency of gemcitabine-related AEs was 
no higher than expected. Only one patient at the RD discontinued treatment due to a 
related AE (grade 3 fatigue after 11 cycles, while having complete response). No 
treatment-related deaths occurred at the RD. 
 
Efficacy 
Thirty-eight treated patients were evaluable according to RECIST v 1.1. One CR (3%) 
and 8 PRs (21%) were observed at all dose levels (ORR=24%; 95%CI, 12–40%). 
Furthermore, 21 SDs (55%) were found, with 11 patients (29%) having SD ≥4 months. 
Responses lasted a median of 8.5 months, and 7 were confirmed radiologically. Median 
PFS was 4.2 months (95%CI, 2.7–6.5 months). The PM01183/gemcitabine combination 
showed antitumor activity across most tumor types, particularly non-small cell lung 
cancer (NSCLC) (ORR=29%, 95%CI, 10–56%) and ovarian cancer (ORR=40%, 
95%CI, 5–85%) (Table 4). 
 
Pharmacokinetics 
All patients were sampled for PK analysis but 5 patients had high PM01183 and 
gemcitabine concentrations and could not be included in the NCA analysis; all dFdU 
concentrations were adequately quantified. PM01183 had lineal PK, with no trend to 
increase or decrease with dose. Mean (standard deviation) total body clearance (CL) 
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results were 11.5 (6.0), 13.4 (8.2), 11.6 (5.7) for PM01183 2.5, 3.0 (RD), 3.5 mg FD 
plus gemcitabine 800 mg/m2, respectively, and 9.4 (5.3) for PM01183 3.5 mg FD plus 
gemcitabine 1000 mg/m2 (Table 5). The mean (standard deviation) BSA dose 
corresponded to 1.7 (0.2) mg/m² at the RD. A similar mean (standard deviation) CL, 
12.5 (7.1) L/h, was found at the RD in the FiH study, thus suggesting that gemcitabine 
did not affect the PK profile of PM01183 [12]. 
No significant differences were found between plasma PM01183 concentrations 
on Day 8 and Day 15, suggesting that drug accumulation is unlikely. Most patients 
(91%) had non-quantifiable PM01183 plasma concentrations on Day 22 of Cycle 1. No 
dose exposure relationship was observed in Cycle 1 using the dose versus area under the 
curve (AUC) and maximum plasma concentration (Cmax) in Cycle 1, probably because 
of large interpatient variability and the similarity of the dose levels explored. 
Gemcitabine PK was similar to that reported for gemcitabine alone or in 
combination, with a mean half-life of 0.2 h. At the RD, mean half-life and AUC for 
dFdU were 20.3 h and 277.0 h*µg/mL, respectively. These values were higher than 
those reported in other studies, maybe because the last sample with quantifiable dFdU 
concentrations in the present study was collected 48 h after infusion, while in other 
studies it was collected close to 24 h after infusion [15-17]. The mean (standard 
deviation) CL of dFdU at the RD in this study was 5.6 (1.4) L/h (Table 5). Therefore, 
PM01183 did not seem to affect the PK of gemcitabine or dFdU. 
Nadir and baseline neutrophil and platelet values in Cycle 1 were also evaluated: 
neutropenia was not related to PM01183 AUC but was related to dFdU AUC (p<0.05). 
Thrombocytopenia was not found to be related to exposure. Finally, PFS was not found 
to be linked to either PM01183 or dFdU AUC.  
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DISCUSSION 
Myelosuppression was the most frequent and relevant toxicity observed with the 
PM01183/gemcitabine combination in this study, and showed a clear dose relationship. 
At the RD (PM01183 3.0 mg FD/gemcitabine 800 mg/m²), this combination delivered 
80% of the standard gemcitabine combination dose (1000 mg/m2) and 60% of the RD 
for single-agent PM01183 (5.0 mg FD) in d1,8 q3wk schedules [13,18,19]. Patients in 
this study did not require primary G-CSF prophylaxis, but they had adequate bone 
marrow function at baseline. Furthermore, patients aged >75 years, ECOG PS >1, and 
>2 prior chemotherapy-containing lines had been excluded from the study.  
The antitumor activity observed with the PM01183/gemcitabine combination in 
this study provides proof-of-concept and justifies further evaluation in prospectively-
defined settings. Gemcitabine has shown activity in breast, pancreatic, ovarian, and 
NSCLC, with ORRs of 10–48% [20-23]. For most tumors in this study, the ORR with 
the combination is slightly higher than that found with gemcitabine alone, although the 
small sample size resulted in wide confidence intervals. The responses observed in 
NSCLC (one CR and 4 PR among 19 patients; ORR=29%, 95% CI, 10–56%) compares 
favorably with second-line cytotoxics such as docetaxel or pemetrexed (with ORRs 
usually below 8%) [24]. Late therapies for both squamous and non-squamous NSCLC 
comprise mutation-driven strategies and immune checkpoint inhibitors, but second- and 
later line strategies are still needed [25,26]. 
PM01183 has shown single-agent activity in platinum-resistant ovarian cancer 
patients (ORR=30%; 95% CI, 16–49%) and in BRCA-1 or 2 germline mutation breast 
cancer (ORR=40%; 95% CI 25–57%) in previous studies [27,28]. In this study, 
antitumor activity was observed both in platinum-resistant ovarian cancer (2 PR and one 
SD ≥4 months) and in metastatic breast cancer (one PR and 3 SD ≥4 months in 2 
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patients with triple-negative disease and 2 with hormone receptor positive/HER 
negative disease). PM01183, gemcitabine, and dFdU PK findings were similar to results 
from single-agent trials and no drug-drug interaction was suggested. This was expected 
as PM01183 has a very low urine excretion (<1% recovery dose after i.v. infusion) and 
is probably metabolized in the liver and dFdU is excreted in urine and its elimination 
depends on renal function. 
Myelosuppression is a common toxicity for both PM01183 and gemcitabine. In 
this trial, however, no relationship between AUC and observed neutropenia was 
established probably because PK data for NCA were only available for Day 1 of Cycle 
1, because of AUC variability, and because of the similarity of the dose levels explored. 
On the other hand, dFdU exposure was seen to be related to neutropenia (but not to 
thrombocytopenia). For the same reasons, PK data did not establish a relationship with 
efficacy results. 
In summary, the RD for the combination is PM01183 3.0 mg FD (or 1.6 
mg/m2)/gemcitabine 800 mg/m² d1,8 q3wk. This schedule is feasible with manageable 
and non-cumulative myelosuppression (mostly severe neutropenia with or without 
severe thrombocytopenia) and active in several tumors, such as NSCLC, ovarian, and 
breast cancer. Further research is warranted to clarify further its potential in the 
treatment of these tumors. 
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TABLES 
Table 1. Baseline characteristics of patients. 
  RD 
(n=11) 
Total   
(n=45) 
Gender   
Male 5 (46%) 24 (53%) 
Female 6 (54%) 21 (47%) 
Median age (range) (years) 56 (38–68) 59 (37–72) 
ECOG performance status    
0 4 (36%) 16 (36%) 
1 7 (64%) 29 (64%) 
Median BSA (range) (m2) 1.9 (1.6–2.2) 1.8 (1.4–2.2) 
Baseline LDH  (range) (IU/L)  224 (156–593) 398 (134–1618) 
Median albumin (range) (g/dL) 4.4 (3.5–4.8) 4.0 (2.6–4.8) 
Primary tumor   
NSCLC 3 (27%) 22 (49%) 
Non-squamous 2 (18%) 21 (47%) 
Squamous 1 (9%) 1 (2%) 
Pancreatic adenocarcinoma 2 (18%) 6 (13%) 
Breast  1 (9%) 6 (13%) 
Triple negative . 2 (4%) 
Hormone receptor-positive and HER2-negative 1 (9%) 4 (9%) 
Ovarian carcinoma 3 (27%) 5 (11%) 
Platinum resistant/refractory 2 (18%) 4 (9%) 
Platinum sensitive 1 (9%) 1 (2%) 
Other a 2 (18%) 6 (13%) 
Median sum of diameter of target lesions (range) 
(mm) 
52 (26–107) 51 (11–142) 
PFS of last prior therapy (range) (months) 3.4 (1.6–21.4) 5.8 (0.9–33.3) 
Median number of lines of prior anticancer therapy 
for advanced disease (range) 
1 (1–2) 1 (0–3) b 
Prior treatment   
Chemotherapy  11 (100%) 42 (93%) b 
Biological therapy 5 (46%) 21 (47%) 
Investigational drug 4 (36%) 11 (24%) 
RD was PM01183 3.0 mg FD (1.6 mg/m²)/gemcitabine 800 mg/m² d1,8 q3wk. 
a Biliary tract adenocarcinoma (n=3), mesothelioma (n=2) and endometrial adenocarcinoma (n=1). 
b Three patients with pancreatic tumors were treated with PM01183/gemcitabine as first-line. 
BSA, body surface area; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; NSCLC, non-
small cell lung cancer; PFS, progression-free survival; q3wk, every 3 weeks; RD, recommended dose; ULN, upper 
limit of normal. 
  
20 
 
Table 2. Dose escalation scheme and dose-limiting toxicity. 
 
PM01183/ 
Gemcitabine 
dose level 
Number of patients 
treated/number 
evaluable for DLT   
Number of 
patients 
with DLT  
% patients with 
DLT/evaluable 
patients (95% CI) 
Dose-limiting toxicity 
2.5 mg FD/ 
800 mg/m2 
4/3 None 0% 
(0–71%)  
. 
3.0 mg FD/ 
800 mg/m2 
(RD) 
11/11 None 0% 
(0–46%) 
. 
3.5 mg FD/ 
800 mg/m2 
21/19 6 32% 
(13–57%)  
Febrile neutropenia (grade 4, n=3; 
grade 3, n=2) 
Thrombocytopenia (grade 4, n=4) 
Hemoptysis (grade 4, n=1) 
Treatment-related death (n=1) 
3.5 mg FD/ 
1000 mg/m2 
9/6 4 67% 
(23–96%) 
Neutropenic infection (grade 4, 
n=1)  
Day-8 infusions omitted 
systematically (n=1) 
Febrile neutropenia (grade 4, n=1) 
Thrombocytopenia (grade 4, n=2) 
Neutropenic sepsis (grade 5, n=1) 
Treatment-related death (n=1). 
CI, confidence interval: DLT, dose-limiting toxicity; FD, flat dose; RD, recommended dose.  
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Table 3. Laboratory abnormalities and treatment-related (or relationship unknown) 
adverse events (in ≥10% of patients) at the recommended dose of the 
PM01183/gemcitabine combination. 
 
Per patient 
(n=11) 
 
Per cycle 
(n=56) 
NCI-CTCAE grade 1 2 3 4 Total  1 2 3 4 Total 
Hematological laboratory abnormalities 
Anemia 2 (18%) 3 (27%) 5 (46%) . 10 (91%)  29 (52%) 16 (29%) 8 (15%) . 53 (95%) 
Neutropenia 3 (27%) 1 (9%) 1 (9%) 5 (46%) 7 (64%)  6 (11%) 7 (13%) 10 (18%) 10 (18%) 33 (59%) 
Thrombocytopenia 6 (55%) 1 (9%) 2 (18%) 1 (9%) 10 (91%)  19 (34%) 7 (13%) 3 (5%) 1 (2%) 30 (54%) 
Biochemical laboratory abnormalities 
ALP increased 3 (27%) 1 (9%) 1 (9%) . 5 (46%)  13 (23%) 5 (9%) 1 (2%) . 19 (34%) 
ALT increased 6 (55%) 3 (27%) 2 (18%) . 11 (100%)  39 (70%) 8 (14%) 2 (4%) . 49 (88%) 
AST increased 10 (91%) . 1 (9%) . 11 (100%)  37 (66%) 1 (2%) 1 (2%) . 39 (70%) 
Creatinine increased 5 (46%) 3 (27%) . . 8 (73%)  17 (30%) 3 (5%) . . 20 (36%) 
Drug-related adverse events 
Constipation 2 (18%) . . . 2 (18%)  3 (5%) . . . 3 (5%) 
Decreased appetite 2 (18%) 1 (9%) . . 3 (27%)  5 (9%) 1 (2%) . . 6 (11%) 
Dysgeusia 3 (27%) . . . 3 (27%)  5 (9%) . . . 5 (9%) 
Edema 2 (18%) .  . 2 (18%)  2 (4%) . . . 2 (4%) 
Fatigue 2 (18%) 4 (36%) 1 (9%) . 7 (64%)  14 (25%) 7 (13%) 1 (2%) . 22 (39%) 
Influenza-like illness . 2 (18%) . . 2 (18%)  1 (2%) 2 (4%) . . 3 (5%) 
Malaise 1 (9%) 1 (9%) . . 2 (18%)  1 (2%) 1 (2%) . . 2 (4%) 
Nausea 4 (36%) 2 (18%) . . 6 (55%)  9 (16%) 3 (5%) . . 12 (21%) 
Peripheral sensory 
neuropathy 
4 (36%) . . . 4 (36%)  6 (11%) . . . 6 (11%) 
Pyrexia 2 (18%) . . . 2 (18%)  3 (5%) . . . 3 (5%) 
Rash 2 (18%) . 1 (9%) . 3 (27%)  3 (5%) . 1 (2%) . 4 (7%) 
Stomatitis 2 (18%) . . . 2 (18%)  3 (5%) . . . 3 (5%) 
Vomiting 2 (18%) 2 (18%)   4 (36%)  4 (7%) 2 (4%) . . 6 (11%) 
The number and percentage of patients/cycles with each adverse event is specified. 
Hematological and biochemical abnormalities are shown regardless of relationship to treatment.  
RD was PM01183 3.0 mg FD (1.6 mg/m²)/gemcitabine 800 mg/m² d1,8 q3wk. 
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; FD, flat dose; NCI-CTCAE, National 
Cancer Institute Common Terminology Criteria for Adverse Events; q3wk, every 3 weeks; RD, recommended dose. 
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Table 4. Overall efficacy as per RECIST v 1.1 by tumor type in evaluable patients 
with 95% confidence interval estimates (n=38). 
 
NSCLC 
(n=17) 
Pancreas  
(n=6) 
Breast  
(n=6) 
Ovarian 
(n=5) 
Other a 
(n=4) 
n % n % n % n % n % 
CR 1 6 . . . . . . . . 
PR 4 24 1 17 1 17 2 40 . . 
SD ≥4 months 5 29 1 17 3 50 1 20 1 25 
<4 months 4 24 2 33 1 17 . . 3 75 
PD 3 18 2 33 1 17 2 40 . . 
ORR b 95% CI 
(range) 
29% 
(10–56%) 
17%  
(0–64%) 
17% 
(0–64%) 
40% 
(5–85%) 
0% 
(0–60%) 
a Biliary tract, mesothelioma, and endometrial. 
b Binomial estimator. 
CI, confidence interval; CR, complete response; NSCLC, non-small cell lung cancer; ORR, overall response rate; PD, 
progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable 
disease. 
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Table 5. Non-compartmental pharmacokinetic parameters of PM01183, gemcitabine, 
and its metabolite, dFdU, by dose level on Day 1 of Cycle 1. 
 
PM01183 mg FD / gemcitabine (mg/m2) 
2.5 / 800 3.0 / 800 (RD) 3.5 / 800 3.5 / 1000 
PM01183 n=2 n=10 n=20 n=8 
Dose (mg/m²) 1.6 (0.0) 1.7 (0.2) 1.9 (0.2) 2.1 (0.3) 
Cmax (µg/L) 92.3 (90.2) 65.6 (28.6) 75.4 (25.4) 78.4 (34.6) 
AUC (h*µg/L) 252.2 (132.4) 304.5 (168.6) 411.1 (311.9) 495.8 (278.2) 
HL (h) 47.6 (1.9) 48.8 (19.1) 51.0 (19.4) 53.1 (24.8) 
CL (L/h) 11.5 (6.0) 13.4 (8.2) 11.6 (5.7) 9.4 (5.3) 
Vss (L) 503.9 (508.7) 532.1 (245.5) 499.9 (292.2) 512.8 (360.2) 
Vz (L) 797.3 (446.1) 886.7 (478) 838.1 (527.6) 714.3 (527.8) 
Gemcitabine n=2 n=10 n=20 n=8 
Cmax (µg/mL) 24.9 (17.5) 13.9 (8.5) 12.9 (6.8) 13.2 (6.6) 
AUC (h*µg/mL) 9.5 (5.7) 6.3 (3.5) 5.8 (2.6) 6.7 (2.9) 
HL (h) 0.5 (0.1) 0.2 (0.1) 0.3 (0.2) 0.3 (0.1) 
CL (L/h) 164.0 (95.9) 321.2 (277.8) 324.6 (208.7) 362.2 (306.4) 
Vss (L) 60.1 (46.6) 119.9 (119.8) 118.6 (78.8) 137.2 (119.0) 
Vz (L) 116.9 (41.1) 105.7 (84.9) 147.8 (112.8) 185.3 (222.1) 
dFdU n=4 n=11 n=22 n=8 
Cmax (µg/mL) 28.9 (8.7) 24.4 (2) 26.5 (5.3) 34.8 (8.7) 
AUC (h*µg/mL) 275.7 (83.5) 277.0 (96.7) 284.4 (69.4) 364.3 (131.7) 
HL (h) 20.0 (5.6) 20.3 (3.9) 21.2 (4.2) 18.2 (3.3) 
CL (L/h) 5.5 (1.6) 5.6 (1.4) 5.4 (1.6) 5.6 (2.8) 
Vss (L) 139.3 (40.2) 140.8 (32.1) 145.5 (36.3) 124.5 (49.3) 
Vz (L) 152.8 (37.3) 161.5 (42.6) 163.2 (44.8) 141.0 (64.4) 
Values are expressed as mean (standard deviation).  
AUC, area under the concentration-time curve from time zero to infinity; CL, total body clearance; Cmax, maximum plasma 
concentration; FD, flat dose; HL, terminal half-life; RD, recommended dose; Vss, volume of distribution at steady-state; Vz, volume 
of distribution based on the terminal half-life. 
 
